MHMarc Hild

Marc Hild

*This is an algorithmically generated author record based on publicly available information.

Marc Hild has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A conformation-sensitive product inhibitor of HDAC1/2 potentiates WNT signaling

    by Olga Charlat, Ling Li, Zheng Zhou, Rohan Ej Beckwith, Lijian Feng, Liqing Geng, Aleem Fazal, Jason R. Thomas, Jason Murphy, Nicolas Pizzato, et al.

    Pharmacological enhancement of WNT/β-catenin signaling holds promises for tissue repair and regeneration. Here, we identify WNA1, an isoxazole-based small molecule, as a potent activator of WNT/β-catenin signaling. WNA1 stimulates β-catenin signaling in WNT-dependent manner and promotes skin hair growth in vivo. Intriguingly, WNA1 increases histone acetylation with minimal activity on uncomplexed recombinant histone deacetylases (HDACs), while conventional HDAC inhibitors exhibit minimal β-catenin-stabilizing activity. We demonstrate that β-catenin signaling is repressed by the HDAC1/2-containing NuRD complex and WNA1 enhances β-catenin signaling by selectively inhibiting HDAC1/2. Structural and biochemical analyses reveal that WNA1 is hydrolyzed by the HDAC1-MTA1 complex and its product is trapped in the foot pocket of HDAC1 in an inositol-hexaphosphate-dependent manner. HDAC1 mutants with reduced foot pocket abrogate WNA1-induced histone acetylation and β-catenin accumulation. These findings establish WNA1 as a conformation-sensitive, foot-pocket-anchored product inhibitor selectively targeting complex-bound HDAC1/2 and reveal a unique mechanism for HDAC1/2 inhibition and WNT potentiation.


  • Open Access

    An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion

    by Caroline Gubser Keller, Youngah Shin, Alex Mas Monteys, Nicole Renaud, Martin Beibel, Natalia Teider, Thomas Peters, Thomas Faller, Sophie St-Cyr, Judith Knehr, et al.

    Huntington’s Disease (HD) is a progressive neurodegenerative disorder caused by CAG trinucleotide repeat expansions in exon 1 of the huntingtin (HTT) gene. The mutant HTT (mHTT) protein causes neuronal dysfunction, causing progressive motor, cognitive and behavioral abnormalities. Current treatments for HD only alleviate symptoms, but cerebral spinal fluid (CSF) or central nervous system (CNS) delivery of antisense oligonucleotides (ASOs) or virus vectors expressing RNA-induced silencing (RNAi) moieties designed to induce mHTT mRNA lowering have progressed to clinical trials. Here, we present an alternative disease modifying therapy the orally available, brain penetrant small molecule branaplam. By promoting inclusion of a pseudoexon in the primary transcript, branaplam lowers mHTT protein levels in HD patient cells, in an HD mouse model and in blood samples from Spinal Muscular Atrophy (SMA) Type I patients dosed orally for SMA (NCT02268552). Our work paves the way for evaluating branaplam’s utility as an HD therapy, leveraging small molecule splicing modulators to reduce expression of dominant disease genes by driving pseudoexon inclusion.


  • Open Access

    Engineering digitizer circuits for chemical and genetic screens in human cells

    by Nicole M. Wong, Elizabeth Frias, Frederic D. Sigoillot, Justin H. Letendre, Marc Hild, Wilson W. Wong

    Cell-based transcriptional reporters are invaluable in high-throughput compound and CRISPR screens for identifying compounds or genes that can impact a pathway of interest. However, many transcriptional reporters have weak activities and transient responses. This can result in overlooking therapeutic targets and compounds that are difficult to detect, necessitating the resource-consuming process of running multiple screens at various timepoints. Here, we present RADAR, a digitizer circuit for amplifying reporter activity and retaining memory of pathway activation. Reporting on the AP-1 pathway, our circuit identifies compounds with known activity against PKC-related pathways and shows an enhanced dynamic range with improved sensitivity compared to a classical reporter in compound screens. In the first genome-wide pooled CRISPR screen for the AP-1 pathway, RADAR identifies canonical genes from the MAPK and PKC pathways, as well as non-canonical regulators. Thus, our scalable system highlights the benefit and versatility of using genetic circuits in large-scale cell-based screening.


  • An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity

    by Seth Carbonneau, Sujata Sharma, Liaomin Peng, Vaisakh Rajan, Dominik Hainzl, Martin Henault, Chian Yang, Jacob Hale, Janine Shulok, John Tallarico, et al.


  • CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism

    by Hyelim Cho, Qiong Shen, Lydia H. Zhang, Mikiko Okumura, Akinori Kawakami, Jessi Ambrose, Frederic Sigoillot, Howard R. Miller, Scott Gleim, Amanda Cobos-Correa, et al.


  • Open Access

    DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery

    by Chaoyang Ye, Daniel J. Ho, Marilisa Neri, Chian Yang, Tripti Kulkarni, Ranjit Randhawa, Martin Henault, Nadezda Mostacci, Pierre Farmer, Steffen Renner, et al.

    Here we report Digital RNA with pertUrbation of Genes (DRUG-seq), a high-throughput platform for drug discovery. Pharmaceutical discovery relies on high-throughput screening, yet current platforms have limited readouts. RNA-seq is a powerful tool to investigate drug effects using transcriptome changes as a proxy, yet standard library construction is costly. DRUG-seq captures transcriptional changes detected in standard RNA-seq at 1/100th the cost. In proof-of-concept experiments profiling 433 compounds across 8 doses, transcription profiles generated from DRUG-seq successfully grouped compounds into functional clusters by mechanism of actions (MoAs) based on their intended targets. Perturbation differences reflected in transcriptome changes were detected for compounds engaging the same target, demonstrating the value of using DRUG-seq for understanding on and off-target activities. We demonstrate DRUG-seq captures common mechanisms, as well as differences between compound treatment and CRISPR on the same target. DRUG-seq provides a powerful tool for comprehensive transcriptome readout in a high-throughput screening environment.


  • Open Access

    Indolyl-Pyridinyl-Propenone-Induced Methuosis through the Inhibition of PIKFYVE

    by Hyelim Cho, Erin Geno, Maude Patoor, Adam Reid, Rick McDonald, Marc Hild, Jeremy L. Jenkins

    Methuosis is a form of nonapoptotic cell death characterized by the accumulation of macropinosome-derived vacuoles. Herein, we identify PIKFYVE, a class III phosphoinositide (PI) kinase, as the protein target responsible for the methuosis-inducing activity of indolyl-pyridinyl-propenones (3-(5-methoxy-2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one). We further characterize the effects of chemical substitutions at the 2- and 5-indolyl positions on cytoplasmic vacuolization and PIKFYVE binding and inhibitory activity. Our study provides a better understanding of the mechanism of methuosis-inducing indolyl-pyridinyl-propenones.


  • Open Access

    Size uniformity of animal cells is actively maintained by a p38 MAPK-dependent regulation of G1-length

    by Shixuan Liu, Miriam Bracha Ginzberg, Nish Patel, Marc Hild, Bosco Leung, Zhengda Li, Yen-Chi Chen, Nancy Chang, Yuan Wang, Ceryl Tan, et al.

    Animal cells within a tissue typically display a striking regularity in their size. To date, the molecular mechanisms that control this uniformity are still unknown. We have previously shown that size uniformity in animal cells is promoted, in part, by size-dependent regulation of G1 length. To identify the molecular mechanisms underlying this process, we performed a large-scale small molecule screen and found that the p38 MAPK pathway is involved in coordinating cell size and cell cycle progression. Small cells display higher p38 activity and spend more time in G1 than larger cells. Inhibition of p38 MAPK leads to loss of the compensatory G1 length extension in small cells, resulting in faster proliferation, smaller cell size and increased size heterogeneity. We propose a model wherein the p38 pathway responds to changes in cell size and regulates G1 exit accordingly, to increase cell size uniformity.


  • Open Access

    Size uniformity of animal cells is actively maintained by a p38 MAPK-dependent regulation of G1-length

    by Shixuan Liu, Miriam Bracha Ginzberg, Nish Patel, Marc Hild, Bosco Leung, Yen-Chi Chen, Zhengda Li, Nancy Chang, Shulamit Diena, Yuan Wang, et al.

    Animal cells within a tissue typically display a striking regularity in their size. To date, the molecular mechanisms that control this uniformity are still unknown. We have previously shown that size uniformity in animal cells is promoted, in part, by size-dependent regulation of G1 length. To identify the molecular mechanisms underlying this process, we performed a large-scale small molecule screen and found that the p38 MAPK pathway is involved in coordinating cell size and cell cycle progression. Small cells display higher p38 activity and spend more time in G1 than larger cells. Inhibition of p38 MAPK leads to loss of the compensatory G1 length extension in small cells, resulting in faster proliferation, smaller cell size and increased size heterogeneity. We propose a model wherein the p38 pathway responds to changes in cell size and regulates G1 exit accordingly, to increase cell size uniformity. One-sentence summary: The p38 MAP kinase pathway coordinates cell growth and cell cycle progression by lengthening G1 in small cells, allowing them more time to grow before their next division.